Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as powerful agents in the management of type 2 diabetes mellitus (T2DM), offering glycemic control with added cardiovascular and renal benefits. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.